A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy

ICT-107 consists of dendritic cells, prepared from autologous mononuclear cells that are pulsed with six synthetic peptides that were derived from tumor associated antigens (TAA) present on glioblastoma tumor cells. This is a Phase 3 study to evaluate ICT-107 in patients with newly diagnosed glioblastoma. Subjects will be randomized to receive standard of care chemoradiation (temozolomide (TMZ) with either ICT-107 or a blinded control. Reinfusion with the pulsed dendritic cells should stimulate cytotoxic T cells to specifically target glioblastoma tumour cells.

开始日期2024-12-01

申办/合作机构

Precision Life Sciences Group

[+1]

NCT01280552

/ Completed临床2期

A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation

This is a phase 2, multicenter study to determine the safety and efficacy of ICT-107 in treating a type of brain tumor called Glioblastoma Multiforme (GBM). ICT-107 is an immunotherapy in which the patient's immune response will be stimulated to kill the tumor cells. Patients must be newly diagnosed with GBM and not yet received chemoradiation. Some of the patient's white blood cells (WBC) will be removed and cultured in a laboratory with purified antigens, similar to those on GBM cells. The patient's own WBC/DC that have been exposed to the tumor antigens will then be given back to the patient as a vaccine over several months. The goal is for the ICT-107 vaccine to stimulate the patient's immune response to kill the remaining GBM tumor cells after surgery and chemotherapy.

开始日期2011-01-01

申办/合作机构

Precision Life Sciences Group

100 项与 ICT-107 相关的临床结果

登录后查看更多信息

100 项与 ICT-107 相关的转化医学

登录后查看更多信息

100 项与 ICT-107 相关的专利（医药）

登录后查看更多信息

项与 ICT-107 相关的文献（医药）

2020-08-01·Translational Cancer Research

Vaccines against glioblastoma: reflections on the ICT-107 phase IIb trial

Communications

作者: De Vleeschouwer, Steven

2019-10-01·Clinical Cancer Research1区 · 医学

A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma

1区 · 医学

Article

作者: Glantz, Michael ; Peereboom, David M. ; Pan, Edward ; Curry, William T. ; Wen, Patrick Y. ; Pinilla, Clemencia ; Reardon, David A. ; Santos, Radleigh G. ; Markert, James M. ; Phuphanich, Surasak ; Landolfi, Joseph C. ; Muzikansky, Alona ; Zhu, Jay-Jiguang ; Kim, Lyndon ; Lesser, Glenn J. ; Gruber, Michael ; Kesari, Santosh ; LaRocca, Renato ; Armstrong, Terri S. ; Yu, John S. ; Aiken, Robert D. ; Fink, Karen ; O'Rourke, Donald M.

AbstractPurpose:To evaluate the results of the randomized, double-blind, placebo-controlled phase II clinical trial of ICT-107 in patients with newly diagnosed glioblastoma.Patients and Methods:We conducted a double-blinded randomized phase II trial of ICT-107 in newly diagnosed patients with glioblastoma (GBM) and tested efficacy, safety, quality of life (QoL), and immune response. HLA-A1+ and/or -A2+–resected patients with residual tumor ≤1 cm3 received radiotherapy and concurrent temozolomide. Following completion of radiotherapy, 124 patients, randomized 2:1, received ICT-107 [autologous dendritic cells (DC) pulsed with six synthetic peptide epitopes targeting GBM tumor/stem cell–associated antigens MAGE-1, HER-2, AIM-2, TRP-2, gp100, and IL13Rα2] or matching control (unpulsed DC). Patients received induction ICT-107 or control weekly × 4 followed by 12 months of adjuvant temozolomide. Maintenance vaccinations occurred at 1, 3, and 6 months and every 6 months thereafter.Results:ICT-107 was well tolerated, with no difference in adverse events between the treatment and control groups. The primary endpoint, median overall survival (OS), favored ICT-107 by 2.0 months in the intent-to-treat (ITT) population but was not statistically significant. Progression-free survival (PFS) in the ITT population was significantly increased in the ICT-107 cohort by 2.2 months (P = 0.011). The frequency of HLA-A2 primary tumor antigen expression was higher than that for HLA-A1 patients, and HLA-A2 patients had higher immune response (via Elispot). HLA-A2 patients achieved a meaningful therapeutic benefit with ICT-107, in both the MGMT methylated and unmethylated prespecified subgroups, whereas only HLA-A1 methylated patients had an OS benefit.Conclusions:PFS was significantly improved in ICT-107–treated patients with maintenance of QoL. Patients in the HLA-A2 subgroup showed increased ICT-107 activity clinically and immunologically.

2019-09-01·Cancer Immunology Research1区 · 医学

An Anticancer Drug Cocktail of Three Kinase Inhibitors Improved Response to a Dendritic Cell–Based Cancer Vaccine

1区 · 医学

Article

作者: Guo, Jitao ; Davila, Eduardo ; Swanson, Steven J. ; Muse, Elena ; Christians, Allison J.

AbstractMonocyte-derived dendritic cell (moDC)–based cancer therapies intended to elicit antitumor T-cell responses have limited efficacy in most clinical trials. However, potent and sustained antitumor activity in a limited number of patients highlights the therapeutic potential of moDCs. In vitro culture conditions used to generate moDCs can be inconsistent, and moDCs generated in vitro are less effective than natural DCs. On the basis of our study highlighting the ability for certain kinase inhibitors to enhance tumor antigenicity, we therefore screened kinase inhibitors for their ability to improve DC immunogenicity. We identified AKT inhibitor MK2206, DNA-PK inhibitor NU7441, and MEK inhibitor trametinib as the compounds most effective at modulating moDC immunogenicity. The combination of these drugs, referred to as MKNUTRA, enhanced moDC activity over treatment with individual drugs while exhibiting minimal toxicity. An evaluation of 335 activation and T-cell–suppressive surface proteins on moDCs revealed that MKNUTRA treatment more effectively matured cells and reduced the expression of tolerogenic proteins as compared with control moDCs. MKNUTRA treatment imparted to ICT107, a glioblastoma (GBM) DC-based vaccine that has completed phase II trials, an increased ability to stimulate patient-derived autologous CD8+ T cells against the brain tumor antigens IL13Rα2(345-354) and TRP2(180-188). In vivo, treating ICT107 with MKNUTRA, prior to injection into mice with an established GBM tumor, reduced tumor growth kinetics. This response was associated with an increased frequency of tumor-reactive lymphocytes within tumors and in peripheral tissues. These studies broaden the application of targeted anticancer drugs and highlight their ability to increase moDC immunogenicity.

项与 ICT-107 相关的新闻（医药）

2025-04-10

·今日头条

DC疫苗为脑瘤患者抢下黄金缓冲期！还有CAR-T、硼中子等重创脑瘤 DC疫苗、CAR-T、硼中子俘获疗法和电场疗法为脑瘤患者带来希望。 1. DC疫苗 DC疫苗ICT-107为胶质母细胞瘤患者延长无进展生存期。 2. CAR-T细胞疗法 CAR-T细胞疗法CARv3-TEAM-E可显

DC疫苗为脑瘤患者抢下黄金缓冲期！还有CAR-T、硼中子等重创脑瘤 DC疫苗、CAR-T、硼中子俘获疗法和电场疗法为脑瘤患者带来希望。 1. DC疫苗 DC疫苗ICT-107为胶质母细胞瘤患者延长无进展生存期。 2. CAR-T细胞疗法 CAR-T细胞疗法CARv3-TEAM-E可显著缩小肿瘤体积。 3. 硼中子俘获疗法 BNCT可精准爆破肿瘤，提高复发性胶质母细胞瘤患者生存率。 4. 电场疗法 TTFields通过电场干扰癌细胞活动，为患者提供无创治疗。

细胞疗法免疫疗法疫苗ASH会议

2025-04-10

·今日头条

DC疫苗为脑瘤患者抢下黄金缓冲期！还有CAR-T、硼中子等重创脑瘤

胶质母细胞瘤作为最常见的恶性原发性脑肿瘤，即便采取最优治疗方案，患者预后仍不容乐观，中位总生存期（OS）仅约14-18个月（2-5）。其根源在于肿瘤细胞群具有高度异质性，因此，靶向多种抗原的治疗策略被视为降低肿瘤逃逸风险的关键。而ICT-107是一种极具潜力的自体树突状细胞（DC）免疫疗法，可同时靶向肿瘤及癌症干细胞上的六种关键抗原——MAGE-1、AIM-2、HER2/neu、TRP-2、IL13Rα2和gp100。这一特性恰好匹配胶质母细胞瘤的异质性特征，为攻克肿瘤逃逸难题提供了新思路。《临床癌症研究》公布的II期临床试验（NCT01280552）数据显示，ICT-107疗法应用于新诊断胶质母细胞瘤患者时展现显著潜力，为这类难治性患者带来了突破性希望！一、ICT-107树突状细胞疫苗：为胶质母细胞瘤患者抢下2.2个月无进展“黄金期” 《临床癌症研究》报道的这项研究，共纳入124例新诊断胶质母细胞瘤患者，均为HLA-A1+和/或-A2+亚型，且术后残留肿瘤体积≤1cm³。患者中位年龄为59.2岁（范围22.9-81.8岁），将其随机分为两组：81例接受标准治疗联合ICT-107免疫疗法（试验组），43例接受标准治疗联合安慰剂（对照组）。结果显示：试验完成时（67例事件），ICT-107组主要终点中位总生存期（OS）为17.0个月（CI：13.68-20.61），对照组为15.0个月（CI 12.33-23.05），差异无统计学意义（HR=0.87，P=0.58）。然而， ICT-107的次要终点中位无进展生存期（PFS）为11.2个月（CI：8.22-13.05），与对照组的9.0个月（CI：5.52-10.29）相比，有显著延长（HR=0.57；P =0.011；详见下图）。 ▲图源“Clin Cancer Res”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除二、CAR-T、电场疗法、硼中子俘获疗法三大抗癌“重器”齐发力，全面围剿胶质母细胞瘤除了上文提到的DC细胞疫苗外，还有CAR-T 细胞疗法、肿瘤电场治疗（TTFields）、硼中子俘获疗法（BNCT）等“抗癌黑科技”，同样在胶质母细胞瘤的战场上大放异彩！（一）CAR-T细胞：为胶质母细胞瘤患者撕开生命新出口，肿瘤“腰斩式”缩小60% CARv3-TEAM-E是一种靶向表皮生长因子受体变体Ⅲ（EGFRvIII）的CAR-T细胞疗法。其第二代CAR结构精准锁定EGFRvIII，同时分泌T细胞接合抗体分子（TEAM）靶向胶质母细胞瘤中表达的野生型EGFR，并能重定向调节性T细胞协同抗肿瘤。《新英格兰医学杂志（NEJM）》刊发的Ⅰ期临床研究（由美国麻省总医院癌症中心联合神经外科开展），披露了CARv3-TEAM-E疗法治疗3例复发性胶质母细胞瘤的初步数据。令人振奋的是，所有患者在输注后2-5天内均出现肿瘤显著缩小！以其中1例72岁的男性患者为例，该患者因阅读困难就诊，后确诊EGFRvIII阳性胶质母细胞瘤，虽历经开颅手术、放疗及替莫唑胺化疗，疾病仍在初诊20个月后出现进展，遂入组接受CARv3-TEAM-E治疗。结果显示：该患者输注CARv3-TEAM-E第2天，MRI显示，肿瘤横截面积缩小18.5% ；治疗第69天，肿瘤较基线（治疗前）骤减60.7% （详见下图）。且在无糖皮质激素或抗血管生成干预下，缓解持续超150天（近6个月）。此外，脑脊液液体活检证实，该患者肿瘤标志物EGFRvIII与EGFR水平同步下降。 ▲图源“NEJM”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除（二）硼中子俘获疗法：精准爆破复发性胶质母细胞瘤，1年生存率高达79.2%，远超传统疗法1倍硼中子俘获疗法（BNCT）是针对脑和头颈部恶性肿瘤的创新粒子治疗技术。其原理基于稳定硼同位素（¹⁰B）与低能热中子反应，生成两束射程仅约10微米（相当于细胞直径）的重粒子——阿尔法粒子与锂粒子（⁷Li³⁺）。这一特性使辐射效应精准局限于硼化合物富集区域，理论上大幅降低对正常组织的损伤，实现细胞级“定点爆破”。临床数据证实，BNCT能在保护正常细胞的同时靶向摧毁肿瘤，显著延长胶质母细胞瘤（GBM）等难治性癌症患者的生存期并提升安全性。《神经肿瘤学进展》发布的一项Ⅱ期临床试验数据尤为亮眼，本次研究共入组27例复发性胶质母细胞瘤患者（24例为经典型GB），中位年龄49.5岁（范围：25–68岁），中位肿瘤体积7.3mL（范围：1.3–30.0mL）。结果显示：复发性GB患者的中位总生存期（OS）达18.9个月（95%CI：12.9-无法估计）， 1年生存率更是高达79.2% （95%CI：57.0-90.8），较贝伐单抗组（中位OS仅为10.5个月，1年生存率仅为34.5%）提升超1倍！ ▼胶质母细胞瘤患者的总体生存率 ▲图源“Neurooncol Adv”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除其中一位63岁的女性患者极具代表性，该患者因左颞叶胶质母细胞瘤，相继接受手术、放疗及替莫唑胺（TMZ）标准治疗。但14个月后，肿瘤复发，遂入组接受硼中子俘获疗法（BNCT）治疗。结果显示：治疗1年后，肿瘤得到有效控制，虽因放射损伤出现脑肿胀，但经贝伐单抗（BEV）干预后水肿稳定。随访3年，患者神经系统状态保持稳定，生活质量显著改善（详见下图）。 ▲图源“Neurooncol Adv”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除（三）电场疗法：助胶质母细胞瘤患者重拾希望，7个月显著缓解病情肿瘤电场疗法（TTFields）是一种便携无创的局部物理治疗手段。患者通过在皮肤表面粘贴特殊绝缘电极贴片，即可产生穿透组织的低强度中频电场，通过干扰癌细胞内类似“马达”的关键构件，从根源上阻断癌细胞的转移与扩散。其最大优势在于居家可操作，患者无需频繁往返医院，治疗与日常生活互不干扰。 ▼电场疗法组成及佩戴示例图 ▲图源“MDPI”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除《临床肿瘤护理杂志（CJON）》曾记录过一则经典病例：一名28岁男性因癫痫发作及意识恢复迟缓就医，MRI显示右侧颞叶与顶叶交界处存在病变。经高剂量类固醇及左乙拉西坦（Keppra®）稳定病情后，患者接受开颅肿瘤切除术，病理确诊为胶质母细胞瘤。术后，患者先完成放化疗，间隔一月后开启为期一年的替莫唑胺（TMZ）辅助化疗。6年后，因右手间歇性颤抖而复查，MRI发现原肿瘤区域出现一个2.2cm×1.5cm强化病灶，二次手术后病理证实为复发性胶质母细胞瘤，并伴放射后改变。经神经肿瘤科团队多方案评估（含临床试验选项），患者最终选择肿瘤电场疗法（TTFields）。令人振奋的是，治疗7个月后，患者恢复状况良好（详见下图）。 ▼该患者在电场疗法治疗前后的MRI对比 ▲图源“MDPI”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除二、小编寄语树突状细胞（DC）是机体内唯一能够激活初始T细胞的抗原提呈细胞，在机体的免疫反应中扮演着举足轻重的角色。不过现阶段，大多DC疫苗还处于早期临床试验阶段；但也有一些国家，已将树突细胞疫苗正式投入临床应用。对于部分早期肿瘤患者而言，在手术后可考虑采用树突细胞联合放化疗的辅助治疗方案，这有助于清除残留的癌细胞，形成免疫记忆，从而有效预防癌症的复发和转移。三、参考资料 [1]Wen PY,et al.A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma. Clin Cancer Res. 2019 Oct 1;25(19):5799-5807. https://pmc-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/articles/PMC8132111/ [2]Choi BD,et al.Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma. N Engl J Med. 2024 Mar 13. https://www-nejm-org.libproxy1.nus.edu.sg/doi/10.1056/NEJMoa2314390?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed [3]Kawabata S,et al.Accelerator-based BNCT for patients with recurrent glioblastoma: a multicenter phase II study. Neurooncol Adv. 2021 May 20;3(1):vdab067. https://pmc-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/articles/PMC8209606/ [4]Schwartz M A,et al.Rationale and Background on Tumor-Treating Fields for Glioblastoma[J]. Clinical Journal of Oncology Nursing, 2016, 20(5). https://www.ons.org/publications-research/cjon/20/5/supplement-october-2016-glioblastoma-treatment/rationale-and 本文为全球肿瘤医生网原创，未经授权禁止转载。

免疫疗法疫苗细胞疗法临床结果临床2期

2022-06-17

·PRNewswire

Biologic Therapy Market Information: By Product and Geography - Global Forecast till 2025

NEW YORK, June 17, 2022 /PRNewswire/ -- One of the key factors driving the Biologic Therapy Market growth is the strong R&D pipeline. The efficiency of biologics in the treatment of severe infections, malignancies, and immunological and hormonal disorders is encouraging manufacturers to invest in R&D for the development of biologics. For instance, monoclonal antibodies constitute one of the fastest-growing segments amongst biological therapies. To date, 88 monoclonal antibodies have been approved for different indications. Some of the examples are ICT-107 for glioblastoma, VGX-3100 for cervical cancer, NeuVax for breast cancer, NexVax2 for celiac disease, CRS-207 for pancreatic cancer, PEV7 for recurrent vulvovaginal candidiasis, and GI-4000 for pancreatic cancer. Similar is the case of biologics meant to be used as vaccines and therapeutic proteins, the pipeline of vendors like AbbVie, Amgen, Johnson & Johnson, and F. Hoffmann-La Roche clearly indicate huge investments in R&D. Apart from manufacturers that are actively involved in research on biologics, many research institutes are also engaged in developing novel biologics through industrial collaborations. Technavio has announced its latest market research report titled Biologic Therapeutics Market by Product and Geography - Forecast and Analysis 2021-2025 Get more information on Macro & Micro Economic Factor Analysis, Statistical Tools, and Trend Projection at Affordable Pricing options. Learn More The Biologic Therapy Market value is set to grow by USD 226.61 billion, progressing at a CAGR of 11% from 2020 to 2025, as per the latest report by Technavio. Moreover, the market is segmented by product (antibody therapeutics, vaccines, cell therapy, gene therapy, and other therapies) and geography (North America, Europe, Asia, and ROW). Biologic Therapy Market 2021-2025: Segmentation Product Antibody Therapeutics Vaccines Cell Therapy Gene Therapy Other Therapies The biologic therapy market share growth by antibody therapeutics will be significant during the forecast period. Monoclonal antibodies are amongst the most widely sold biologics and are even referred to as the future of medicine. Monoclonal antibodies are cloned from single-parent cells and are designed to recognize and bind to specific receptors on the surface of the cells. This specificity in action makes monoclonal antibodies more effective than conventional treatments for immunological and chronic ailments like cancer. Owing to these factors, it is expected that the global biologic therapy market will grow during the forecast period. Geography North America Europe Asia ROW 57% of the market's growth will originate from North America during the forecast period. The US is the key market for biologic therapy in North America. Market growth in this region will be slower than the growth of the market in the Asia region. One of the reasons for market growth in the Americas is the increased incidence of chronic diseases. The rise in the prevalence of major health disorders is mainly due to lifestyle changes and increased consumption of alcohol and tobacco in the US. However, market growth is expected to be only gradual due to the patent expiry of major biologics present in the market. Biologic Therapy Market 2021-2025: Scope Biologic Therapy Market size Biologic Therapy Market trends Biologic Therapy Market analysis High cost of biologics is one of the key challenges hindering the biologic therapy market growth. Biologics can be used for the treatment of several types of malignancies, hormonal imbalances, and autoimmune conditions, but they are expensive, which makes them beyond the reach of the economically underprivileged. The total manufacturing costs, which include the costs related to the clinical trials associated with biologics, account for vendors offering these products at high costs. The development of a biological molecule requires a separate living organism. Though bacterial production is not that costly, the production of therapeutic agents like monoclonal antibodies and vaccines becomes costly as they involve animal handling. The immunization of the animal and other procedures related to the production of antibodies and vaccines increases the cost of that product. Due to the high price of biologic therapy, many patients are unable to access this effective therapy, and this will remain a major challenge for the market during the forecast period. Biologic Therapy Market 2021-2025: Vendor Analysis The report analyzes the market's competitive landscape and offers information on several market vendors, including: AbbVie Inc. AstraZeneca Plc Bristol-Myers Squibb Co. F. Hoffmann-La Roche Ltd. GlaxoSmithKline Plc Johnson and Johnson Inc. Merck and Co. Inc. Novartis AG Pfizer Inc. Sanofi SA The biologic therapy market is concentrated and the vendors are deploying growth strategies such as partnering with research organizations and hospitals for R&D to compete in the market. Biologic Therapy Market 2021-2025: Key Highlights CAGR of the market during the forecast period 2021-2025 Detailed information on factors that will assist biologic therapy market growth during the next five years Estimation of the biologic therapy market size and its contribution to the parent market Predictions on upcoming trends and changes in consumer behavior The growth of the biologic therapy market Analysis of the market's competitive landscape and detailed information on vendors Comprehensive details of factors that will challenge the growth of biologic therapy market vendors Related Reports: Head and Neck Cancer Diagnostics Market by Diagnostic Methods and Geography - Forecast and Analysis 2020-2024: The head and neck cancer diagnostics market size has the potential to grow by USD 3.41 billion during 2020-2024. The market's growth momentum will accelerate throughout the forecast period. Latest Exclusive Research Insights Here Global Spine Biologics Market 2018-2022: The global spine biologics market size will grow by USD 418.72 million during 2018-2022. This industry research report provides a detailed analysis of the market based on product (bone grafts, BMP, BMAC, and others) and geography (the Americas, APAC, and EMEA). Latest Exclusive Research Insights Here Table of Contents: 1 Executive Summary 2 Market Landscape 2.1 Market ecosystem Exhibit 01: Parent market Exhibit 02: Market characteristics 2.2 Value chain analysis 3 Market Sizing 3.1 Market definition Exhibit 03: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 04: Market segments 3.3 Market size 2020 3.4 Market outlook: Forecast for 2020 - 2025 Exhibit 05: Global - Market size and forecast 2020 - 2025 ($ billion) Exhibit 06: Global market: Year-over-year growth 2020 - 2025 (%) 3.5 Market by application 4 Five Forces Analysis 4.1 Five forces summary Exhibit 07: Five forces analysis 2020 & 2025 4.2 Bargaining power of buyers Exhibit 08: Bargaining power of buyers 4.3 Bargaining power of suppliers Exhibit 09: Bargaining power of suppliers 4.4 Threat of new entrants Exhibit 10: Threat of new entrants 4.5 Threat of substitutes Exhibit 11: Threat of substitutes 4.6 Threat of rivalry Exhibit 12: Threat of rivalry 4.7 Market condition Exhibit 13: Market condition - Five forces 2020 5 Market Segmentation by Product 5.1 Market segments Exhibit 14: Product - Market share 2020-2025 (%) 5.2 Comparison by Product Exhibit 15: Comparison by Product 5.3 Antibody therapeutics - Market size and forecast 2020-2025 Exhibit 16: Antibody therapeutics - Market size and forecast 2020-2025 ($ billion) Exhibit 17: Sales of major monoclonal antibodies 2018-2020 ($ million) Exhibit 18: Antibody therapeutics - Year-over-year growth 2020-2025 (%) 5.4 Vaccines - Market size and forecast 2020-2025 Exhibit 19: Vaccines - Market size and forecast 2020-2025 ($ billion) Exhibit 20: Vendors offering vaccines Exhibit 21: Vaccines - Year-over-year growth 2020-2025 (%) 5.5 Cell therapy - Market size and forecast 2020-2025 Exhibit 22: Cell therapy - Market size and forecast 2020-2025 ($ billion) Exhibit 23: Cell therapy - Year-over-year growth 2020-2025 (%) 5.6 Gene therapy - Market size and forecast 2020-2025 Exhibit 24: Gene therapy - Market size and forecast 2020-2025 ($ billion) Exhibit 25: Gene therapy - Year-over-year growth 2020-2025 (%) 5.7 Other therapies - Market size and forecast 2020-2025 Exhibit 26: Other therapies - Market size and forecast 2020-2025 ($ billion) Exhibit 27: Other therapies - Year-over-year growth 2020-2025 (%) 5.8 Market opportunity by Product Exhibit 28: Market opportunity by Product 6 Customer landscape 7 Geographic Landscape 7.1 Geographic segmentation Exhibit 30: Market share by geography 2020-2025 (%) 7.2 Geographic comparison Exhibit 31: Geographic comparison 7.3 North America - Market size and forecast 2020-2025 Exhibit 32: North America - Market size and forecast 2020-2025 ($ billion) Exhibit 33: North America - Year-over-year growth 2020-2025 (%) 7.4 Europe - Market size and forecast 2020-2025 Exhibit 34: Europe - Market size and forecast 2020-2025 ($ billion) Exhibit 35: Europe - Year-over-year growth 2020-2025 (%) 7.5 Asia - Market size and forecast 2020-2025 Exhibit 36: Asia - Market size and forecast 2020-2025 ($ billion) Exhibit 37: Asia - Year-over-year growth 2020-2025 (%) 7.6 ROW - Market size and forecast 2020-2025 Exhibit 38: ROW - Market size and forecast 2020-2025 ($ billion) Exhibit 39: ROW - Year-over-year growth 2020-2025 (%) 7.7 Key leading countries Exhibit 40: Key leading countries 7.8 Market opportunity by geography Exhibit 41: Market opportunity by geography ($ billion) 8 Drivers, Challenges, and Trends 8.1 Market drivers 8.2 Market challenges Exhibit 43: Impact of drivers and challenges 8.3 Market trends 9 Vendor Landscape 9.1 Overview Exhibit 44: Vendor landscape 9.2 Landscape disruption Exhibit 45: Landscape disruption Exhibit 46: Industry risks 10 Vendor Analysis 10.1 Vendors covered Exhibit 47: Vendors covered 10.2 Market positioning of vendors Exhibit 48: Market positioning of vendors 10.3 AbbVie Inc. Exhibit 49: AbbVie Inc. - Overview Exhibit 50: AbbVie Inc. - Product and service Exhibit 51: AbbVie Inc. – Key news Exhibit 52: AbbVie Inc. - Key offerings 10.4 AstraZeneca Plc Exhibit 53: AstraZeneca Plc - Overview Exhibit 54: AstraZeneca Plc - Product and service Exhibit 55: AstraZeneca Plc – Key news Exhibit 56: AstraZeneca Plc - Key offerings 10.5 Bristol-Myers Squibb Co. Exhibit 57: Bristol-Myers Squibb Co. - Overview Exhibit 58: Bristol-Myers Squibb Co. - Product and service Exhibit 59: Bristol-Myers Squibb Co. – Key news Exhibit 60: Bristol-Myers Squibb Co. - Key offerings 10.6 F. Hoffmann-La Roche Ltd. Exhibit 61: F. Hoffmann-La Roche Ltd. - Overview Exhibit 62: F. Hoffmann-La Roche Ltd. - Business segments Exhibit 63: F. Hoffmann-La Roche Ltd. – Key news Exhibit 64: F. Hoffmann-La Roche Ltd. - Key offerings Exhibit 65: F. Hoffmann-La Roche Ltd. - Segment focus 10.7 GlaxoSmithKline Plc Exhibit 66: GlaxoSmithKline Plc - Overview Exhibit 67: GlaxoSmithKline Plc - Business segments Exhibit 68: GlaxoSmithKline Plc – Key news Exhibit 69: GlaxoSmithKline Plc - Key offerings Exhibit 70: GlaxoSmithKline Plc - Segment focus 10.8 Johnson and Johnson Inc. Exhibit 71: Johnson and Johnson Inc. - Overview Exhibit 72: Johnson and Johnson Inc. - Business segments Exhibit 73: Johnson and Johnson Inc. – Key news Exhibit 74: Johnson and Johnson Inc. - Key offerings Exhibit 75: Johnson and Johnson Inc. - Segment focus 10.9 Merck and Co. Inc. Exhibit 76: Merck and Co. Inc. - Overview Exhibit 77: Merck and Co. Inc. - Business segments Exhibit 78: Merck and Co. Inc. – Key news Exhibit 79: Merck and Co. Inc. - Key offerings Exhibit 80: Merck and Co. Inc. - Segment focus 10.10 Novartis AG Exhibit 81: Novartis AG - Overview Exhibit 82: Novartis AG - Business segments Exhibit 83: Novartis AG – Key news Exhibit 84: Novartis AG - Key offerings Exhibit 85: Novartis AG - Segment focus 10.11 Pfizer Inc. Exhibit 86: Pfizer Inc. - Overview Exhibit 87: Pfizer Inc. - Business segments Exhibit 88: Pfizer Inc. – Key news Exhibit 89: Pfizer Inc. - Key offerings 10.12 Sanofi SA Exhibit 90: Sanofi SA - Overview Exhibit 91: Sanofi SA - Business segments Exhibit 92: Sanofi SA – Key news Exhibit 93: Sanofi SA - Key offerings Exhibit 94: Sanofi SA - Segment focus 11 Appendix 11.1 Scope of the report 11.2 Currency conversion rates for US$ Exhibit 95: Currency conversion rates for US$ 11.3 Research methodology Exhibit 96: Research Methodology Exhibit 97: Validation techniques employed for market sizing Exhibit 98: Information sources 11.4 List of abbreviations Exhibit 99: List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

疫苗基因疗法抗体细胞疗法合作

100 项与 ICT-107 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
多形性胶质母细胞瘤	临床3期	加拿大	Precision Life Sciences Group	2024-12-01
多形性胶质母细胞瘤	临床3期	奥地利	Precision Life Sciences Group	2024-12-01
多形性胶质母细胞瘤	临床3期	美国	Precision Life Sciences Group	2024-12-01
胶质母细胞瘤	临床3期	西班牙	ImmunoCellular Therapeutics Ltd.	-
胶质母细胞瘤	临床3期	荷兰	ImmunoCellular Therapeutics Ltd.	-
胶质母细胞瘤	临床3期	奥地利	ImmunoCellular Therapeutics Ltd.	-
胶质母细胞瘤	临床3期	加拿大	ImmunoCellular Therapeutics Ltd.	-
胶质母细胞瘤	临床3期	美国	ImmunoCellular Therapeutics Ltd.	-
胶质母细胞瘤	临床3期	德国	ImmunoCellular Therapeutics Ltd.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01280552 (Pubmed \| Clin Cancer Res) 人工标引	临床2期	胶质母细胞瘤 HLA-A02 Positive	124	six synthetic peptide+ICT-107	(網顧糧衊淵構鹹構衊糧) = 鑰鏇鹽獵襯網築廠蓋顧範夢淵鬱壓願繭糧築鑰 (膚積艱鹽壓網鑰簾鑰網 ) 更多	积极	2019-10-01
				six synthetic peptide	-
ASCO2014	临床2期	多形性胶质母细胞瘤	124	ICT-107	(鑰艱顧衊廠夢製網憲築) = 壓憲淵艱顧廠醖願範廠顧遞淵糧製簾蓋積艱衊 (選廠鑰網簾淵鹹齋鹹廠 ) 更多	积极	2014-05-20
				Control (unpulsed DC)	(鑰艱顧衊廠夢製網憲築) = 繭網餘壓構襯顧積鏇範顧遞淵糧製簾蓋積艱衊 (選廠鑰網簾淵鹹齋鹹廠 )
ICT-107 (ASCO2011)	临床1期	胶质母细胞瘤	16	ICT-107	(餘顧壓糧顧衊選觸艱鏇) = 壓製鏇糧築簾顧積遞壓衊鏇顧構選選鹽遞願壓 (選餘窪鹹衊願壓製廠鹹 )	-	2011-05-20